This chapter delves into the ethical and social implications of employing nanotechnology in the management of various strategies such as prevention, diagnosis, and therapeutics of metabolic syndrome (MetS). MetS is obesity, insulin resistance, dyslipidaemia, and hypertension. Though nanotechnology provides innovative approaches relevant to drug delivery, tissue regeneration and diagnostics, it’s paramount to address the concerns about its safety, challenges and social view. The present chapter explains insights about how nanoscale innovations are transforming clinical outcomes along with their associated risks. In addition, readers gain insight into the unique ethical challenges that arise in the context of metabolic health, especially related to data privacy, accessibility, informed consent, and public perception. Real-world studies, clinical trial metrics, and statistical evidence are presented to underscore both the promise and potential pitfalls of nanotechnology for its applications in MetS. The chapter concludes with actionable recommendations for responsible innovation in this emerging field.